[{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"d089607a-1031-4001-af05-f61c61e55845","acronym":"","url":"https://clinicaltrials.gov/study/NCT02013648","created_at":"2021-01-18T09:12:24.696Z","updated_at":"2024-07-02T16:35:17.930Z","phase":"Phase 3","brief_title":"Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)","source_id_and_acronym":"NCT02013648","lead_sponsor":"University of Ulm","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 204","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-02-23"},{"id":"9a349e3d-c04d-4a0c-8ba8-e2c65537d627","acronym":"RETRO-CBF","url":"https://clinicaltrials.gov/study/NCT05070208","created_at":"2021-10-07T12:53:00.876Z","updated_at":"2024-07-02T16:35:21.574Z","phase":"","brief_title":"Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor","source_id_and_acronym":"NCT05070208 - RETRO-CBF","lead_sponsor":"Acute Leukemia French Association","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"],"overall_status":"Completed","enrollment":" Enrollment 400","initiation":"Initiation: 09/22/2021","start_date":" 09/22/2021","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2024-01-31"},{"id":"f066ba35-63f6-465c-8eac-446af1756f24","acronym":"MOSAIC","url":"https://clinicaltrials.gov/study/NCT04385290","created_at":"2021-01-18T21:10:20.677Z","updated_at":"2025-02-25T15:43:59.383Z","phase":"Phase 1/2","brief_title":"Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","source_id_and_acronym":"NCT04385290 - MOSAIC","lead_sponsor":"Technische Universität Dresden","biomarkers":" FLT3 • RUNX1 • RUNX1T1","pipe":" | ","alterations":" CD33 expression","tags":["FLT3 • RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 09/04/2020","start_date":" 09/04/2020","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-08-09"},{"id":"25edff0a-7f77-4f28-8cdb-a05b5d2c6066","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821738","created_at":"2023-04-20T14:03:53.744Z","updated_at":"2024-07-02T16:35:48.599Z","phase":"Phase 2","brief_title":"Avapritinib in CBF-AML With KIT Mutations","source_id_and_acronym":"NCT05821738","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" KIT • RUNX1 • RUNX1T1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-05-09"},{"id":"344dd84f-cbb2-4195-9057-7e6bb67aba39","acronym":"","url":"https://clinicaltrials.gov/study/NCT01238211","created_at":"2021-01-18T04:59:02.957Z","updated_at":"2024-07-02T16:35:54.402Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01238211","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RUNX1 • RUNX1T1","pipe":" | ","alterations":" RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 12/14/2010","start_date":" 12/14/2010","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 03/15/2021","study_completion_date":" 03/15/2021","last_update_posted":"2023-03-01"},{"id":"15653fe0-b83a-48f1-b49b-deecd67286da","acronym":"","url":"https://clinicaltrials.gov/study/NCT05404516","created_at":"2022-06-03T11:55:37.644Z","updated_at":"2024-07-02T16:36:09.374Z","phase":"Phase 2","brief_title":"Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML","source_id_and_acronym":"NCT05404516","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" RUNX1 • RUNX1T1","pipe":"","alterations":" ","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • idarubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-06-03"},{"id":"44766fc1-3509-4938-9c77-565abb1837ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT02926586","created_at":"2021-01-18T14:22:28.719Z","updated_at":"2024-07-02T16:36:10.613Z","phase":"Phase 4","brief_title":"Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML","source_id_and_acronym":"NCT02926586","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" RUNX1 • RUNX1T1","pipe":"","alterations":" ","tags":["RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 08/16/2020","primary_completion_date":" 08/16/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-05-11"},{"id":"27458ff0-85c5-41f5-8711-e378e1f3bd84","acronym":"","url":"https://clinicaltrials.gov/study/NCT05361057","created_at":"2022-05-05T00:56:33.542Z","updated_at":"2024-07-02T16:36:10.999Z","phase":"Phase 2","brief_title":"Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients","source_id_and_acronym":"NCT05361057","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" NPM1 • RUNX1 • RUNX1T1 • NUP214 • DEK","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • RUNX1 • RUNX1T1 • NUP214 • DEK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2022-05-04"},{"id":"28f437aa-8eaa-459d-8b43-29719db9a821","acronym":"","url":"https://clinicaltrials.gov/study/NCT02450877","created_at":"2021-01-18T11:45:03.113Z","updated_at":"2024-07-02T16:36:52.205Z","phase":"Phase 2","brief_title":"A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.","source_id_and_acronym":"NCT02450877","lead_sponsor":"Celgene","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • RUNX1T1","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 10/10/2018","primary_completion_date":" 10/10/2018","study_txt":" Completion: 10/08/2019","study_completion_date":" 10/08/2019","last_update_posted":"2019-12-20"}]